Journal of Genetic Medicine

Korean Society of Medical Genetics and Genomics (대한의학유전학회)
권호 표지
DOI QR코드

DOI QR Code

A case of Noonan syndrome diagnosed using the facial recognition software (FACE2GENE)

  • Kim, Soo Kyoung (Department of Pediatrics, Soonchunhyang University Seoul Hospital) ;
  • Jung, So Yoon (Department of Pediatrics, Soonchunhyang University Seoul Hospital) ;
  • Bae, Seong Phil (Department of Pediatrics, Soonchunhyang University Seoul Hospital) ;
  • Kim, Jieun (Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital) ;
  • Lee, Jeongho (Department of Pediatrics, Soonchunhyang University Seoul Hospital) ;
  • Lee, Dong Hwan (Department of Pediatrics, Soonchunhyang University Seoul Hospital)
  • Received : 2019.11.19
  • Accepted : 2019.12.02
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Clinicians often have difficulties diagnosing patients with subtle phenotypes of Noonan syndrome phenotypes. Facial recognition technology can help in the identification of several genetic syndromes with facial dysmorphic features, especially those with mild or atypical phenotypes. A patient visited our clinic at 5 years of age with short stature. She was administered growth hormone treatment for 6 years, but her growth curve was still below the 3rd percentile. She and her mother had wide-spaced eyes and short stature, but there were no other remarkable features of a genetic syndrome. We analyzed their photographs using a smartphone facial recognition application. The results suggested Noonan syndrome; therefore, we performed targeted next-generation sequencing of genes associated with short stature. The results showed that they had a mutation on the PTPN11 gene known as the pathogenic mutation of Noonan syndrome. Facial recognition technology can help in the diagnosis of Noonan syndrome and other genetic syndromes, especially in patients with mild phenotypes.

Keywords

References

  1. Allanson JE, Hall JG, Hughes HE, Preus M, Witt RD. Noonan syndrome: the changing phenotype. Am J Med Genet 1985;21:507-14. https://doi.org/10.1002/ajmg.1320210313
  2. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013;381:333-42. https://doi.org/10.1016/S0140-6736(12)61023-X
  3. Bhambhani V, Muenke M. Noonan syndrome. Am Fam Physician 2014;89:37-43.
  4. Lee BH, Yoo HW. Noonan syndrome and RASopathies: clinical features, diagnosis and management. J Genet Med 2019;16:1-9. https://doi.org/10.5734/JGM.2019.16.1.1
  5. Hammond P. The use of 3D face shape modelling in dysmorphology. Arch Dis Child 2007;92:1120-6. https://doi.org/10.1136/adc.2006.103507
  6. Gurovich Y, Hanani Y, Bar O, Nadav G, Fleischer N, Gelbman D, et al. Identifying facial phenotypes of genetic disorders using deep learning. Nat Med 2019;25:60-4. https://doi.org/10.1038/s41591-018-0279-0
  7. Kruszka P, Porras AR, Addissie YA, Moresco A, Medrano S, Mok GTK, et al. Noonan syndrome in diverse populations. Am J Med Genet A 2017;173:2323-34. https://doi.org/10.1002/ajmg.a.38362
  8. Koh AL, Tan ES, Brett MS, Lai AHM, Jamuar SS, Ng I, et al. The spectrum of genetic variants and phenotypic features of Southeast Asian patients with Noonan syndrome. Mol Genet Genomic Med 2019;7:e00581. https://doi.org/10.1002/mgg3.581
  9. Ko JM, Kim JM, Kim GH, Yoo HW. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 2008;53:999-1006. https://doi.org/10.1007/s10038-008-0343-6
  10. Giacomozzi C, Deodati A, Shaikh MG, Ahmed SF, Cianfarani S. The impact of growth hormone therapy on adult height in Noonan syndrome: a systematic review. Horm Res Paediatr 2015;83:167-76. https://doi.org/10.1159/000371635
  11. Seo GH, Yoo HW. Growth hormone therapy in patients with Noonan syndrome. Ann Pediatr Endocrinol Metab 2018;23:176-81. https://doi.org/10.6065/apem.2018.23.4.176
  12. Ozono K, Ogata T, Horikawa R, Matsubara Y, Ogawa Y, Nishijima K, et al. Efficacy and safety of two doses of $Norditropin^{(R)}$ (somatropin) in short stature due to Noonan syndrome: a 2-year randomized, double-blind, multicenter trial in Japanese patients. Endocr J 2018;65:159-74. https://doi.org/10.1507/endocrj.EJ17-0313